



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
09/896,004	06/29/2001	Aruna Nathan	ETH-1572	1514	
27777 75	90 09/21/2005		EXAMINER .		
PHILIP S. JOI	HNSON	LEVY, NEIL S			
JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA			ART UNIT	PAPER NUMBER	
NEW BRUNSWICK, NJ 08933-7003			1615		
			DATE MAILED: 09/21/2003	DATE MAILED: 09/21/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

		ノ			
	Application No.	Applicant(s)			
	09/896,004	NATHAN ET AL.			
Office Action Summary	Examiner	Art Unit			
	NEIL LEVY	1615			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 16(a). In no event, however, may a reply be tim rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).			
Status		·			
 Responsive to communication(s) filed on 30 Ju This action is FINAL. Since this application is in condition for alloware closed in accordance with the practice under E 	action is non-final. ace except for formal matters, pro				
Disposition of Claims					
4)	vn from consideration. ted. election requirement. r. epted or b) objected to by the I drawing(s) be held in abeyance. See on is required if the drawing(s) is ob	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 3/08/04.	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:				

Art Unit: 1615

DETAILED ACTION

Claims 32,34,36-38,42 ,43,57,59,61 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 4-7,9,10,14,23,24 of copending Application No. 10/183260. Although the conflicting claims are not identical, they are not patentably distinct from each other because both applications claim the same polymeric wax carrier, obvious to apply in known means of therapeutic dosage forms.

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Claims 32,34,36,37, provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claim1-5 of copending Application No. 10325768. Although the conflicting claims are not identical, they are not patentably distinct from each other because The applications present in essence the same compositions, with obvious variation in melting point within the control of the artisan to adjust in order to provide a harder or softer medical dosage form.

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Claims 32,34,36-38,59,60 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 3-6,8-12,14-17,20 of copending Application No. 10178970. Although the conflicting claims

are not identical, they are not patentably distinct from each other because the now allowed '970 application claims the same components, thus would have the same waxy branching & pendent groups, as obvious to the artisan to provide depending upon the drug delivery form desired.

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Applicant's arguments filed 6/30/05 have been fully considered but they are not persuasive. The amendments have overcome the 112 and prior art rejections of record, however applicant has persued copending claims obvious over the now claimed invention. The claims are not the same in applicant's copending applications or patents of record. Note no date @ Mark reference on IDS, please provide.

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Art Unit: 1615

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to NEIL LEVY whose telephone number is 571-272-0619. The examiner can normally be reached on Tuesday-Friday, 7 AM to 5:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, THURMAN PAGE can be reached on 571-272-0602. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 09/896,004

Business Center (EBC) at 866-217-9197 (toll-free).

Art Unit: 1615

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic

NEIL LEVY
Primary Examiner

Page 5

Art Unit 1615
